Tonight, I watched the London Calling 2024 session about EPI2ME workflows. The title was “Product demo: Integrated EPI2ME: streamlined analysis for clinical and biopharma applications.” Matt Parker from ONT is a clinical scientist. They spoke about AmPORE-TB, human variation workflows, and mRNA vaccine quality control. The tuberculosis workflow aims to rapidly identify antimicrobial resistance in hours. The system targets first-line antibiotics and several TB genes. The session included a live demo. The user loads a sample sheet. With two hours of sequencing and thirty minutes of processing, AmPORE-TB generates a detailed report. For each sample, a list of antibiotic resistance profiles is generated. Allele frequency and coverage information are computed. Sirisha Hesketh described an upcoming integration with MinKNOW. Multiple workflows can be selected. Comprehensive outputs include alignments, variant calls, coverage summaries, and HTML reports. Hesketh shared a repeat plot that was added based on user feedback and clinical collaboration. Upcoming integrations with third-party analyses will provide more analyses. Hesketh shared how the next release of MinKNOW will include data analysis integration. Within MinKNOW, a user can select workflows that will run after sequencing. Currently, mRNA vaccine QC includes coverage and identity information. I love how the HTML reports are becoming even more user-friendly and include details about the analysis.
